ASND vs. ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, VTRS, and QGEN
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry.
Ascendis Pharma A/S vs. Its Competitors
argenex (NASDAQ:ARGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.
argenex has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
argenex has a net margin of 40.20% compared to Ascendis Pharma A/S's net margin of -93.22%. argenex's return on equity of 16.15% beat Ascendis Pharma A/S's return on equity.
In the previous week, argenex had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 19 mentions for argenex and 5 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.20 beat argenex's score of 0.46 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.
60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
argenex presently has a consensus price target of $729.93, suggesting a potential upside of 33.47%. Ascendis Pharma A/S has a consensus price target of $220.67, suggesting a potential upside of 27.31%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Ascendis Pharma A/S.
argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.
Summary
argenex beats Ascendis Pharma A/S on 13 of the 17 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
This page (NASDAQ:ASND) was last updated on 7/2/2025 by MarketBeat.com Staff
